Analysis and comparison of statin prescription patterns and outcomes according to clinical department

Journal of Clinical Pharmacy and Therapeutics
H-S KimI Y Choi

Abstract

There is a disparity between the Korean treatment guidelines and actual clinical prescription habits. This study was designed to evaluate the department-specific disparities and achievement rates for low-density lipoprotein cholesterol (LDL-C) targets, based on each department's specific statin prescription patterns. We retrospectively evaluated data from 31 718 patients who had been prescribed a statin at least once between January 2008 and June 2013 at our institution. Patients were classified into the high-risk (target LDL-C < 100 mg/dL) or moderate-risk (target LDL-C < 130 mg/dL) groups, according to the National Cholesterol Education Programme-Adult Treatment Panel III guidelines. Statins were most commonly prescribed in the cardiology (32·0%) and endocrinology (26·6%) departments. For the high-risk group, 70% of patients in the cardiology, endocrinology and cardiac surgery departments achieved their target LDL-C levels (<100 mg/dL). However, the target achievement rates in most other departments were <70%. For the moderate-risk group, 79·2% of patients achieved their target levels. Departments that prescribed a greater number of high- or intermediate-potency statins were more likely to achieve their target LDL-C levels. T...Continue Reading

References

Jan 9, 1993·Lancet·R E MorganD L Wingard
Jan 19, 2000·Circulation·D J MaronM F Linton
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Mar 12, 2002·JAMA : the Journal of the American Medical Association·Rajendra H MehtaUNKNOWN GAP Steering Committee of the American College of Cardiology
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators
Oct 30, 2004·American Heart Journal·Lynn A Smaha, UNKNOWN American Heart Association
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Mar 15, 2006·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN ASTEROID Investigators
Apr 4, 2006·The American Journal of Cardiology·Harold Bays
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Pertti J NeuvonenJanne T Backman
Aug 29, 2007·Clinics in Liver Disease·Sidharth S Bhardwaj, Naga Chalasani
Sep 30, 2009·Current Medical Research and Opinion·Leiv OseValerie Arneson
May 12, 2010·Journal of Clinical Pharmacy and Therapeutics·T-C WengS-H Tai
Jan 8, 2014·Endocrinology and Metabolism·Philip J Barter
Jan 10, 2014·Diabetes & Metabolism Journal·Eun RohUNKNOWN Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association

❮ Previous
Next ❯

Citations

Jun 28, 2016·Home Healthcare Now·Diana R Mager
Sep 7, 2017·Healthcare Informatics Research·Joo Young HongIn Young Choi
Mar 4, 2017·Endocrinology and Metabolism·Hun Sung KimKun Ho Yoon

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.